1. Home
  2. VWAV vs FATE Comparison

VWAV vs FATE Comparison

Compare VWAV & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

HOLD

Current Price

$2.93

Market Cap

139.7M

Sector

Technology

ML Signal

HOLD

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$2.40

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAV
FATE
Founded
2024
2007
Country
United States
United States
Employees
12
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
125.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VWAV
FATE
Price
$2.93
$2.40
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.10
AVG Volume (30 Days)
562.1K
4.1M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.88
EPS
N/A
N/A
Revenue
N/A
$6,646,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.13
$0.91
52 Week High
$15.80
$3.23

Technical Indicators

Market Signals
Indicator
VWAV
FATE
Relative Strength Index (RSI) 30.82 43.14
Support Level N/A $1.01
Resistance Level $6.64 $3.22
Average True Range (ATR) 0.34 0.22
MACD -0.07 -0.08
Stochastic Oscillator 0.64 1.19

Price Performance

Historical Comparison
VWAV
FATE

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: